Join BJS Academy
BJS Academy>Randomized clinical ...>Aspirin vs placebo a...
Normal View Dyslexic View

Aspirin vs placebo as adjuvant therapy for breast cancer. The Alliance A011502 randomized trial.

16 August 2024
Randomized clinical trials Breast
Chen WY, Ballman KV, Partridge AH, Hahn OM, Briccetti FM et al.

JAMA 2024; 331: 1714-1721.

Some 3020 women with non-metastatic breast cancer were enrolled. The study was terminated after the first interim analysis for futility. 300mg aspirin per day for a median of 33.8 months did not improve breast cancer recurrence (hazard ratio 1.27, 95 per cent confidence interval 0.99 to 1.63, P=0.06) or survival (1.19, 0.82 to 1.72).

Comment: Theoretical advantage not proven.

BJS Foundation Limited
BJS Academy
0000-0000
BJS Foundation Limited
London, UK
rct275
Randomized clinical trials
Randomized clinical trials
Breast
Aspirin vs placebo as adjuvant therapy for breast cancer. The Alliance A011502 randomized trial.
Chen WY, Ballman KV, Partridge AH, Hahn OM, Briccetti FM et al.
16082024
JAMA 2024; 331: 1714-1721.
Some 3020 women with non-metastatic breast cancer were enrolled. The study was terminated after the first interim analysis for futility. 300mg aspirin per day for a median of 33.8 months did not improve breast cancer recurrence (hazard ratio 1.27, 95 per cent confidence interval 0.99 to 1.63, P=0.06) or survival (1.19, 0.82 to 1.72).
Comment: Theoretical advantage not proven.
Published on: 16 August 2024
Article ID: rct275

Related articles

21-Gene assay to inform chemotherapy benefit in node-positive breast cancer.

Kalinsky K, Barlow WE, Gralow JR, Meric-Bernstam F, Albain KS, Hayes DF et al.
N Engl J Med 2021; 385: 2336-2347

1 January 2022

Event-free survival with pembrolizumab in early triple-negative breast cancer.

Schmid P, Cortes J, Dent R, Pusztai L, McArthur H, Kummel S et al, for the KEYNOTE-522 Investigators.
N Engl J Med 2022; 386: 556-567.

1 March 2022

Aromatase inhibitors versus tamoxifen in premenopausal women with oestrogen receptor-positive early-stage breast cancer treated with ovarian suppression: a patient-level meta-analysis of 7030 women from four randomised trials.

Early Breast Cancer Trialists’ Collaborative Group (EBCTCG).

17 May 2022
Home
  • Normal view
  • Dyslexic view
Info
Copied!